Arvinas develops medicines based on targeted protein degradation, with research across oncology and neurology. Its PROTAC platform is designed to use the body’s protein-disposal system to degrade and remove disease-causing proteins.
Research brief:Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Arvinas develops medicines based on targeted protein degradation, with research across oncology and neurology. Its PROTAC platform is designed to use the body’s protein-disposal system to degrade and remove disease-causing proteins.
Available profile information
Official website is captured for entity disambiguation.
3 official sources linked for verification.
2 supporting sources linked.
5 structured facts available for extraction.
1 product or service signal captured.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.
Sources & evidence
Published statements, observation dates and unresolved questions for this specific profile.
Description of Arvinas’s research platform, not a claim of treatment efficacy, regulatory approval or availability for purchase.
Reviewed against captured first-party source passages by an assistant. This records the organization’s published description; it does not establish independent corroboration or a legal-register match.
Reviewed 2026-10-17 · Review due 2027-01-15 · Version 1
PROTAC terminology
Withdrawn
This fact is not currently established by the evidence in this record.
Published description of Arvinas on the cited official website, observed 2026-10-17.
Withdrawn because its scope mistakenly used the 2026-10-17 review date as the source observation date. The cited sources were captured on 2026-10-16; their original timestamps are preserved. The unchanged supported value is replaced by brandsource:arvinas:depth-chronology-2026-10-17:fact-4.
Reviewed 2026-10-17 · Review due 2027-01-15 · Version 2
PROTAC terminology
Published by the business
PROteolysis TArgeting Chimeras
Published description of Arvinas on the cited official website; observation dates are recorded with each source.
Replaces an earlier record whose scope confused the review date with the source capture date. Content and source observation timestamps are unchanged. Reviewed against captured first-party passages by an assistant; this does not establish independent corroboration or a legal-register match.
Reviewed 2026-10-17 · Review due 2027-01-15 · Version 1
Published overview
Withdrawn
This fact is not currently established by the evidence in this record.
Published description of Arvinas on the cited official website, observed 2026-10-17.
Withdrawn because its scope mistakenly used the 2026-10-17 review date as the source observation date. The cited sources were captured on 2026-10-16; their original timestamps are preserved. The unchanged supported value is replaced by brandsource:arvinas:depth-chronology-2026-10-17:summary.
Reviewed 2026-10-17 · Review due 2027-01-15 · Version 2
Published overview
Published by the business
Arvinas develops medicines based on targeted protein degradation, with research across oncology and neurology. Its PROTAC platform is designed to use the body’s protein-disposal system to degrade and remove disease-causing proteins.
Published description of Arvinas on the cited official website; observation dates are recorded with each source.
Replaces an earlier record whose scope confused the review date with the source capture date. Content and source observation timestamps are unchanged. Reviewed against captured first-party passages by an assistant; this does not establish independent corroboration or a legal-register match.
Reviewed 2026-10-17 · Review due 2027-01-15 · Version 1
Research areas
Withdrawn
This fact is not currently established by the evidence in this record.
Published description of Arvinas on the cited official website, observed 2026-10-17.
Withdrawn because its scope mistakenly used the 2026-10-17 review date as the source observation date. The cited sources were captured on 2026-10-16; their original timestamps are preserved. The unchanged supported value is replaced by brandsource:arvinas:depth-chronology-2026-10-17:fact-3.
Reviewed 2026-10-17 · Review due 2027-01-15 · Version 2
Research areas
Published by the business
Oncology and neurology
Published description of Arvinas on the cited official website; observation dates are recorded with each source.
Replaces an earlier record whose scope confused the review date with the source capture date. Content and source observation timestamps are unchanged. Reviewed against captured first-party passages by an assistant; this does not establish independent corroboration or a legal-register match.